A5061340891- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Breast Lesions and Carcinomas
- Advanced Breast Cancer Therapies
- Monoclonal and Polyclonal Antibodies Research
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- BRCA gene mutations in cancer
- Cancer Cells and Metastasis
- Ovarian cancer diagnosis and treatment
- Epigenetics and DNA Methylation
- Cancer-related Molecular Pathways
- Gastric Cancer Management and Outcomes
- Global Cancer Incidence and Screening
- Genetic factors in colorectal cancer
- RNA modifications and cancer
- Estrogen and related hormone effects
- Radiomics and Machine Learning in Medical Imaging
- Reproductive Biology and Fertility
- Lung Cancer Research Studies
- Prostate Cancer Treatment and Research
- PARP inhibition in cancer therapy
Centre Jean Perrin
2016-2025
Université Clermont Auvergne
2016-2025
Inserm
2009-2025
Imagerie Moléculaire et Stratégies Théranostiques
2017-2024
Sigma Clermont
2022
UniCancer Group
2021
Institut Claudius Regaud
2006-2019
Centre Antoine Lacassagne
2007-2019
Institut de Cancérologie de l'Ouest
2015-2019
Centre Léon Bérard
2012-2019
The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel reviewed and endorsed substantial new evidence on aspects of the local regional therapies for early breast cancer, supporting less extensive surgery to axilla shorter durations radiation therapy. It refined its earlier approach classification management luminal disease in absence amplification or overexpression Human Epidermal growth factor Receptor 2 (HER2) oncogene, while retaining essentially unchanged...
Abstract The anti-epidermal growth factor receptor (anti-EGFR) cetuximab has been proven to be efficient in metastatic colorectal cancer. molecular mechanisms underlying the clinical response this drug remain unknown. Genetic alterations of intracellular effectors involved EGFR-related signaling pathways may have an effect on targeted therapy. In study, tumors from 30 cancer patients treated by were screened for KRAS, BRAF, and PIK3CA mutation direct sequencing EGFR copy number chromogenic...
Advanced Breast Cancer (ABC) comprises both locally advanced (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains an incurable disease with a median overall survival of ∼2–3 years 5-year only ∼25% [2–4]. Some more recent series seem to indicate improvement in [5, 6].
Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic (MBC) [1.Cardoso F. Costa A. Norton L. ESO-ESMO 2nd International Consensus Guidelines for (ABC2). Simultaneous publication in.Breast. 2014; 23: 489-502Abstract Full Text PDF PubMed Scopus (252) Google Scholar]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of ∼3 years 5-year only ∼25% [2.Cardoso Spence D. Mertz S. et al.Global analysis...
To investigate the proportion of breast cancers arising in patients with germ line BRCA1 and BRCA2 mutations expressing basal markers developing predictive tests for identification high-risk patients.Histopathologic material from 182 tumors mutation carriers, 63 109 controls, collected as part international Breast Cancer Linkage Consortium were immunohistochemically stained CK14, CK5/6, CK17, epidermal growth factor receptor (EGFR), osteonectin.All five commoner than control (CK14: 61%...
In breast cancer, immunohistochemical assessment of proliferation using the marker Ki67 has potential use in both research and clinical management. However, lack consistency across laboratories limited Ki67's value. A working group was assembled to devise a strategy harmonize analysis increase scoring concordance. Toward that goal, we conducted reproducibility study. Eight received 100 cancer cases arranged into 1-mm core tissue microarrays—one set stained by participating laboratory one...
This study evaluated by immunohistochemistry (IHC) immune cell response during neoadjuvant primary systemic therapy (PST) with trastuzumab in patients HER2-positive breast cancer. In all, 23 IHC 3+ cancer were treated plus docetaxel. Pathological complete and partial responses documented for nine (39%) 14 (61%) patients, respectively. Case-matched controls comprised docetaxel-based PST without (D; n=23) or docetaxel (non-taxane, non-trastuzumab, NT–NT; n=23). All surgical specimens...
Advanced breast cancer (ABC) is a treatable but still generally incurable disease. The goals of care are to optimize both length and quality life. Due continuous research, several advances have been made, particularly for the human epidermal growth factor receptor 2 (HER-2)-positive luminal-like subtypes. Notwithstanding these advances, median overall survival patients with ABC only 2–3 years, although range wide [1–5], may be longer treated in specialized institutions [6].
Purpose The antiepidermal growth factor receptor antibody cetuximab shows activity in irinotecan-refractory metastatic colorectal cancer (mCRC), mainly wild-type KRAS tumors. Cetuximab may also exert antitumor effects through antibody-dependent cell-mediated cytotoxicity (ADCC) which Fc portion interacts with receptors (FcγRs) expressed by immune cells. ADCC is influenced FcγRIIa-H131R and FcγRIIIa-V158F polymorphisms that are clinically relevant follicular lymphoma breast treated rituximab...
Abstract Ki67 immunohistochemistry (IHC), commonly used as a proliferation marker in breast cancer, has limited value for treatment decisions due to questionable analytical validity. The International Breast Cancer Working Group (IKWG) consensus meeting, held October 2019, assessed the current evidence IHC validity and clinical utility including series of scoring studies IKWG conducted on centrally stained tissues. Consensus observations recommendations are: 1) estrogen receptor HER2...
Trastuzumab-based therapy has been shown to confer overall survival benefit in HER2-positive patients with advanced gastric cancer a large multicentric trial (ToGA study). Subgroup analysis identified adenocarcinomas of the stomach and gastroesophageal (GE) junction overexpression HER2 according immunohistochemistry (IHC) as potential responders. Due recent approval trastuzumab for positive metastatic GE-junction Europe (EMEA) diagnostics is now mandatory IHC being primary test followed by...